Skip to main content

RePOOPulation: It's Less 'Icky'

A paper in the inaugural issue of Microbiome describes the effort to develop and design a synthetic stool mixture to treat people with Clostridium difficile infections. Researchers led by the University of Guelph's Emma Allen-Vercoe present their therapy, which they dubbed RePOOPulate.

RePOOPulate, a synthetic, probiotic stool mixture, was developed by examining the microbial diversity of the stool of a healthy 41-year-old woman, finding 33 isolates from commensal species to include in the mixture. It was then used to treat two patients infected with a highly virulent C. difficile strain. The patients "reverted to their normal bowel pattern within 2 to 3 days and remained symptom-free at 6 months," the researchers note.

As a press release notes, "Besides offering an effective therapy against the deadly superbug, the artificial poop is safer, more stable and adaptable, and less 'icky' than treatments for C. difficile infection such as fecal bacteriotherapy."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.